Skip to content

Prime Medicine PRME Comprehensive Income (Loss), Net of Tax, Attributable to Parent

Comprehensive Income (Loss), Net of Tax, Attributable to Parent at other companies

Intellia Therapeutics logo
Intellia TherapeuticsNTLA
-$97.5M+14.4%
CRISPR Therapeutics logo
CRISPR TherapeuticsCRSP
-$129.69M+3.0%
Beam Therapeutics logo
Beam TherapeuticsBEAM
-$96.5M+11.3%
Regenxbio logo
RegenxbioRGNX
-$90.23M-1,589%
PVL
Palvella TherapeuticsPVLA
-$15.76M-92.3%
Monopar Therapeutics logo
Monopar TherapeuticsMNPR
-$3.93M-49.7%

Other financials

Income statement

See full
Revenue$838.0K-61.6%
Operating income-$50.7M+3.3%
Net income-$49.1M+5.3%
EPS (diluted)-$0.28+30.0%

Balance sheet

See full
Cash & equivalents$77.8M-26.6%
Total debt$114.5M-5.5%
Total equity$76.7M-28.3%
Total assets$294.7M-10.2%

Cash flow

See full
Operating cash flow-$42.7M+12.6%
CapEx$214.0K-91.2%
Free cash flow-$42.9M+16.3%

Valuation

See full
Market cap$574.36M+111%
Enterprise value$611.08M+113%
P/S124×+6.3×

Profitability

See full
Operating margin-4,498.1%-1,134pp
Net margin-4,342.4%-1,099pp
FCF margin-3,607.4%

Returns & leverage

See full
Return on equity-216.1%+1,519pp
Debt / equity1.5×+0.4×
Current ratio3.8×-1.0×

Where this comes from

Reported directly by Prime Medicine in its filing.

Tagged under the XBRL concept us-gaap:ComprehensiveIncomeNetOfTax.

The official record: Prime Medicine’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Prime Medicine's comprehensive income (loss), net of tax, attributable to parent.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Prime Medicine's comprehensive income (loss), net of tax, attributable to parent?
Prime Medicine (PRME) reported comprehensive income (loss), net of tax, attributable to parent of -$49.21M in Q1 2026.
How has Prime Medicine's comprehensive income (loss), net of tax, attributable to parent changed year-over-year?
Prime Medicine's comprehensive income (loss), net of tax, attributable to parent increased by 5.2% year-over-year, from -$51.91M to -$49.21M.
What is the long-term trend for Prime Medicine's comprehensive income (loss), net of tax, attributable to parent?
Over 3 years (2022 to 2025), Prime Medicine's comprehensive income (loss), net of tax, attributable to parent has grown at a 18.1% compound annual growth rate (CAGR), from -$122.18M to -$201.06M.
What does comprehensive income (loss), net of tax, attributable to parent mean?
This metric represents the total change in equity from non-owner sources, encompassing both net income and other comprehensive income items such as unrealized gains or losses on investments. It provides a comprehensive view of the company's financial performance by including all recognized revenues, expenses, gains, and losses. This figure is a key indicator of the total economic impact on the company's net assets during a specific period.